 COA |
MSDS |
 HPLC |
NMR |
| CAS No: | 926037-48-1 |
| Molecular formula(MF) | C27H21F3N8O |
| Molecular Weight(MW): | 530.50 |
| Alias |
| In vitro | DMSO | 100 mg/mL (188.5 mM) |
|---|---|---|
| Water | <1 mg/mL | |
| Ethanol | <1 mg/mL | |
| In vivo |
| Description | Radotinib is a selective BCR-ABL1 tyrosine kinase inhibitor with IC50 of 34 nM, used to treat Chronic Myeloid Leukemia. | ||
|---|---|---|---|
| Targets |
|
||
| In vitro |
In vitro, Radotinib binds BCR-ABL1 and reduces phosphorylation of CrkL, a BCR-ABL1 target protein. Radotinib also effectively inhibits the proliferation of common mutant clones of BCR-ABL1, with the exception of T315I. [1] In AML cells, radotinib significantly decreases the cell viability, promotes differentiation, and induces CD11b expression and apoptosis. In NB4, THP-1, and Kasumi-1 cells, radotinib also induces CD11b expression, and decreases the viability. [2] |